Status:
COMPLETED
Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Breast Neoplasms
Neoplasm Metastasis
Eligibility:
FEMALE
18-45 years
Brief Summary
To access the effectiveness of High-dose Cyclophosphamide Combined Chemotherapy combined with adoptive cellular therapy with dentritic and cytokine-induced killer cells in triple negative metastatic b...
Detailed Description
1. Metastatic breast cancer patients should be definitively diagnosis based on histopathology, with ER-negative and PR-negative, FISH testing for her-2-negative 2. All the patients enrolled will be gi...
Eligibility Criteria
Inclusion
- Failure to anthracycline and/or taxol chemotherapy;
- metastatic tumor is histologically confirmed by immunohistochemical staining to be ER-negative and PR-negative. FISH testing for her-2-negative;
- Metastatic tumor can not be removed through surgery procedure;
- Metastatic tumor measured by PET-CT scan is at least 1cm;
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- Normal cardiac, hepatic, renal and bone marrow functions;
- Life expectancy ≥3 months.
Exclusion
- Do not finish twice PET-CT scan;
- Central nervous system metastases;
- Serious or uncontrolled concurrent medical illness;
- History of other malignancies;
- Having been enrolled in some other clinal trials within a month;
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT01232062
Start Date
August 1 2010
End Date
October 1 2013
Last Update
July 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, China, 100142